Veerhealth Care Ltd Upgraded to Hold on Technical and Financial Improvements

Technical Trend Improvement Spurs Upgrade

The primary catalyst for Veerhealth Care’s rating upgrade lies in its technical trend, which has shifted from mildly bullish to bullish. Key technical indicators underpinning this change include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, alongside a bullish Know Sure Thing (KST) indicator on both weekly and monthly timeframes. The daily moving averages also support a positive momentum, reinforcing the stock’s upward trajectory.

While the monthly MACD remains mildly bearish and the Dow Theory signals no clear trend on the weekly chart, the overall technical picture has improved markedly. Bollinger Bands on the monthly chart have turned bullish, suggesting increased volatility in favour of upward price movement. The Relative Strength Index (RSI) remains neutral on both weekly and monthly scales, indicating no immediate overbought or oversold conditions.

These technical signals have translated into tangible price gains, with the stock closing at ₹18.94 on 17 Feb 2026, up 0.64% from the previous close. The stock’s 52-week high stands at ₹23.77, while the low is ₹9.29, highlighting a strong recovery over the past year.

Valuation Reassessment: From Risky to Very Expensive

Alongside technical improvements, Veerhealth Care’s valuation grade has been revised from risky to very expensive. The company currently trades at a price-to-earnings (PE) ratio of 47.95, significantly higher than many peers in the Pharmaceuticals & Biotechnology sector. Its enterprise value to EBITDA ratio stands at 26.51, while the price-to-book value is a modest 1.70.

Despite these elevated multiples, the company’s PEG ratio is an exceptionally low 0.03, reflecting the market’s anticipation of rapid earnings growth relative to its price. However, the latest return on capital employed (ROCE) is negative at -1.73%, and return on equity (ROE) is a modest 3.56%, signalling weak profitability fundamentals that do not fully justify the premium valuation.

Compared to peers such as Indiabulls and Cropster Agro, which also trade at very expensive valuations but with differing fundamentals, Veerhealth Care’s valuation appears stretched. This discrepancy underscores the importance of monitoring the company’s financial performance closely to validate the premium pricing.

Financial Trend: Mixed Signals Amid Positive Quarterly Results

Veerhealth Care has demonstrated positive financial performance in recent quarters, with the latest Q3 FY25-26 results showing encouraging growth. Net sales for the last six months reached ₹11.24 crores, marking a robust 25.03% increase. The company also reported its highest quarterly PBDIT at ₹1.24 crores and PBT less other income at ₹0.78 crores, reflecting improved operational efficiency.

Moreover, the company has posted positive results for four consecutive quarters, signalling a stabilising earnings trend. This has contributed to the stock’s outperformance relative to the broader market, with a 14.86% return over the past year compared to the Sensex’s 9.66% gain. Over three and five years, Veerhealth Care has delivered compounded returns of 62.58% and 364.79%, respectively, far exceeding benchmark indices.

However, long-term fundamental concerns persist. The company’s average ROE over five years is a modest 2.72%, and net sales have grown at an annualised rate of 11.75%, while operating profit growth lags at 7.26%. Additionally, the company’s ability to service debt remains weak, with an average EBIT to interest ratio of -0.28, indicating potential financial strain.

Quality Assessment: Hold Grade Reflects Balanced View

Veerhealth Care’s overall quality grade remains at Hold, reflecting a balanced assessment of its strengths and weaknesses. While the company’s recent operational improvements and market-beating returns are positive, the weak long-term profitability and financial health metrics temper enthusiasm.

The company’s market capitalisation grade is 4, indicating a mid-sized entity with moderate liquidity and investor interest. Majority shareholding remains with non-institutional investors, which may impact stock volatility and trading patterns.

Given these factors, the Hold rating suggests investors should maintain positions with caution, monitoring upcoming quarterly results and market developments closely before considering further exposure.

Technical Outlook and Market Performance

From a technical perspective, Veerhealth Care’s bullish momentum is supported by several indicators. The weekly MACD’s bullish crossover and the KST’s positive readings on both weekly and monthly charts suggest sustained upward price movement. Daily moving averages confirm this trend, while Bollinger Bands on the monthly timeframe indicate expanding volatility in favour of gains.

The stock’s recent price action has outpaced the Sensex and BSE500 indices, with a 5.34% gain over the past month compared to the Sensex’s slight decline of 0.35%. Year-to-date, the stock has marginally underperformed with a -2.02% return versus the Sensex’s -2.28%, but its one-year and longer-term returns remain impressive.

Despite a 10-year return of 149.21% trailing the Sensex’s 259.08%, Veerhealth Care’s five-year return of 364.79% is a standout, underscoring its potential as a growth stock within the Pharmaceuticals & Biotechnology sector.

Valuation Concerns Temper Enthusiasm

While the technical and financial trends have improved, valuation remains a key concern. The company’s very expensive rating is driven by a PE ratio nearly 48 times earnings and an EV to EBIT ratio exceeding 41, signalling that investors are paying a premium for growth expectations. The negative ROCE of -1.73% further highlights inefficiencies in capital utilisation.

Investors should weigh these valuation metrics carefully against the company’s earnings growth and operational improvements. The PEG ratio near zero suggests rapid earnings growth relative to price, but this metric may be distorted by low or negative earnings in prior periods.

Overall, the Hold rating reflects a cautious stance, recognising the stock’s technical strength and recent financial gains while acknowledging the stretched valuation and fundamental risks.

Conclusion: A Balanced Upgrade Reflecting Mixed Fundamentals

Veerhealth Care Ltd’s upgrade from Sell to Hold is primarily driven by improved technical indicators and a reassessment of its valuation profile. The stock’s bullish momentum, supported by positive MACD and KST signals, alongside strong recent quarterly results, has encouraged a more optimistic outlook.

However, the company’s weak long-term profitability, negative ROCE, and very expensive valuation warrant caution. Investors are advised to monitor upcoming financial disclosures and market developments closely before increasing exposure.

With a market cap grade of 4 and a Mojo Score of 50.0, Veerhealth Care remains a stock to watch within the Pharmaceuticals & Biotechnology sector, offering potential upside tempered by fundamental challenges.

Unlock special upgrade rates for a limited period. Start Saving Now →